듀셴형 근이영양증 환자수 분석 및 예측(2026-2035년)

Duchenne Muscular Dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to severe muscle degeneration, loss of ambulation, respiratory complications, cardiomyopathy, and premature mortality. The disease primarily affects males and is among the most common inherited neuromuscular disorders in children. Although DMD remains a rare disease, improvements in diagnosis, disease management, and supportive care are contributing to a growing prevalent patient population worldwide.

Patient population analysis plays a critical role in understanding disease burden, forecasting future treatment demand, supporting clinical trial planning, guiding healthcare resource allocation, and enabling pharmaceutical companies to assess commercial opportunities. As innovative therapies such as gene therapies, exon-skipping drugs, and mutation-specific treatments continue to emerge, accurate patient population forecasting has become increasingly important across the DMD ecosystem.

Market Drivers

Increasing Adoption of Genetic Diagnostics

One of the primary drivers of market growth is the widespread adoption of advanced genetic testing technologies. Improvements in molecular diagnostics, next-generation sequencing, and newborn screening programs are enabling earlier and more accurate identification of DMD patients.

Earlier diagnosis improves disease management and increases the number of identified patients within epidemiological databases and patient registries.

Growing Patient Survival Rates

Advances in multidisciplinary care, respiratory support, cardiac management, corticosteroid treatment, and emerging disease-modifying therapies have significantly improved survival outcomes for DMD patients.

As life expectancy increases, the prevalent patient population continues to expand, creating greater demand for long-term epidemiological monitoring and forecasting.

Expansion of Rare Disease Registries

National and international patient registries are improving the quality of DMD epidemiological data. These registries facilitate patient identification, natural history studies, clinical trial recruitment, and healthcare planning activities.

Growing investments in real-world evidence generation and patient tracking systems are further strengthening population analysis capabilities.

Rising Demand for Precision Medicine

The development of mutation-specific therapies requires detailed understanding of patient subgroups, genetic profiles, disease stages, and regional prevalence patterns.

Patient population analysis is becoming increasingly important for identifying eligible treatment populations and supporting commercialization strategies.

Market Restraints

Underdiagnosis in Emerging Markets

Many low- and middle-income countries continue to face challenges related to limited access to genetic testing, specialist care, and disease awareness.

As a result, a significant number of DMD patients may remain undiagnosed, creating uncertainty in epidemiological estimates.

Variability in Data Collection

Differences in registry coverage, healthcare reporting systems, diagnostic criteria, and epidemiological methodologies can lead to inconsistencies across regions and datasets.

Small Patient Population

As a rare disease, DMD affects a relatively limited number of individuals globally, creating challenges in collecting large-scale epidemiological data and forecasting long-term trends.

Epidemiology and Patient Population Insights

The global DMD patient population remains relatively small compared with common chronic diseases, but the burden on patients, families, and healthcare systems is substantial.

Recent epidemiological analyses estimate that the global prevalence of DMD is approximately 7.1 cases per 100,000 males and 2.8 cases per 100,000 individuals in the general population. Birth prevalence has been estimated at approximately 19.8 cases per 100,000 live male births.

According to industry forecasts, the global DMD patient population is expected to increase from approximately 0.43 million patients in 2026 to approximately 0.54 million patients by 2035, representing a compound annual growth rate (CAGR) of around 2.5%. This growth is primarily attributed to improved diagnosis, increased disease awareness, and longer patient survival.

Historically, DMD has been estimated to affect approximately one in every 3,500-5,000 live male births globally, making it one of the most common inherited neuromuscular disorders among children.

Technology and Segment Insights

The global DMD patient population analysis market can be segmented by patient type, age group, mutation profile, disease stage, data source, end user, and geography.

By patient type, the market includes diagnosed patients, treated patients, untreated patients, ambulatory patients, and non-ambulatory patients. Diagnosed patient populations continue to grow due to improvements in genetic testing and disease awareness.

By age group, the market includes pediatric patients, adolescent patients, and adult patients. Pediatric patients currently account for the largest share of the DMD population, although increasing life expectancy is contributing to growth in adult patient segments.

By mutation profile, patient populations can be categorized according to exon-specific mutations and genetic abnormalities. These classifications are becoming increasingly important as personalized therapies target specific mutation groups.

By disease stage, the market includes early-stage, ambulatory, transitional, non-ambulatory, and advanced-stage patients. Disease-stage analysis supports treatment planning, healthcare resource allocation, and clinical trial design.

By data source, the market includes patient registries, hospital databases, electronic health records, genetic testing databases, insurance claims databases, and epidemiological studies.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, research organizations, academic institutions, contract research organizations, and government agencies.

Advancements in artificial intelligence, predictive analytics, digital health platforms, and real-world evidence technologies are improving patient identification, disease tracking, and long-term population forecasting.

Regional Insights

North America remains a leading region for DMD patient population analysis due to advanced diagnostic infrastructure, strong rare disease awareness, established patient registries, and extensive clinical research activity.

Europe represents a significant market supported by robust healthcare systems, comprehensive patient registries, and active rare disease initiatives. Several European countries maintain well-established neuromuscular disease surveillance programs.

Asia-Pacific is expected to witness the fastest growth in patient identification and epidemiological monitoring. Improvements in healthcare infrastructure, expanding genetic testing availability, and growing awareness of rare diseases are contributing to increased diagnosis rates across countries such as China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving diagnostic capabilities and rare disease surveillance, although access to specialized care remains uneven across several regions.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, rare disease research institutions, pharmaceutical companies, biotechnology firms, and healthcare consulting organizations.

Market participants are increasingly investing in patient registry expansion, real-world evidence generation, digital disease surveillance platforms, and advanced epidemiological analytics. Strategic collaborations among industry stakeholders, healthcare providers, academic institutions, and patient advocacy groups continue to improve data quality and patient identification.

Growing interest in mutation-specific therapies and gene therapies is also increasing demand for highly detailed patient segmentation and forecasting capabilities.

Conclusion

The global Duchenne Muscular Dystrophy patient population analysis market is poised for sustained growth through 2035, supported by expanding diagnostic capabilities, increasing disease awareness, improving survival outcomes, and growing investment in rare disease research. As the global DMD patient population is projected to increase from approximately 0.43 million patients in 2026 to approximately 0.54 million patients by 2035, accurate patient population forecasting will become increasingly important for healthcare planning, clinical development, and commercialization strategies. While challenges related to underdiagnosis and data variability remain, advances in genetic diagnostics, patient registries, real-world evidence platforms, and digital health technologies are expected to significantly enhance future epidemiological analysis and disease monitoring capabilities.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global DMD prevalence, incidence, diagnosed population, and future patient trends.
• Competitive Landscape: Understand epidemiological developments, patient registry expansion, and emerging rare disease initiatives.
• Market Drivers and Future Trends: Assess factors influencing patient population growth and disease identification.
• Actionable Recommendations: Support healthcare planning, clinical development, commercialization, and investment decisions.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, and policy stakeholders.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, and commercialization planning.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Global, regional, and country-level patient population analysis and forecasts
• Prevalence, incidence, diagnosed population, and mutation-specific patient segmentation
• Disease-stage assessment, demographic analysis, and epidemiological trends
• Competitive intelligence, patient registry analysis, and future market opportunity assessment.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Overview of Duchenne Muscular Dystrophy (DMD)
• 1.2 Key Epidemiology Highlights
• 1.3 Patient Population Overview by Region
• 1.4 Major Findings and Strategic Insights
• 1.5 Emerging Trends Influencing Patient Identification and Management
• 1.6 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Duchenne Muscular Dystrophy
  • 2.1.1 Disease Definition
  • 2.1.2 Historical Background
  • 2.1.3 Disease Burden and Unmet Needs
• 2.2 Disease Biology
  • 2.2.1 Genetics and Dystrophin Gene Mutations
  • 2.2.2 Pathophysiology
  • 2.2.3 Disease Progression Stages
• 2.3 Risk Factors and Etiology
  • 2.3.1 Genetic Causes
  • 2.3.2 Family History and Carrier Status
  • 2.3.3 Other Contributing Factors
• 2.4 Clinical Presentation
  • 2.4.1 Early Symptoms
  • 2.4.2 Motor and Functional Decline
  • 2.4.3 Cardiac and Respiratory Complications
  • 2.4.4 Cognitive and Behavioral Manifestations
• 2.5 Diagnosis and Screening
  • 2.5.1 Clinical Assessment
  • 2.5.2 Creatine Kinase Testing
  • 2.5.3 Genetic Testing
  • 2.5.4 Muscle Biopsy
  • 2.5.5 Newborn Screening Initiatives
• 2.6 Epidemiology Analysis
  • 2.6.1 Incidence of DMD
  • 2.6.2 Prevalence of DMD
  • 2.6.3 Diagnosed Prevalent Cases
  • 2.6.4 Age-wise Patient Population
  • 2.6.5 Gender-wise Patient Population
  • 2.6.6 Mutation-specific Patient Population
    • 2.6.6.1 Exon 51 Skipping Amenable Population
    • 2.6.6.2 Exon 53 Skipping Amenable Population
    • 2.6.6.3 Exon 45 Skipping Amenable Population
    • 2.6.6.4 Other Mutation Types
  • 2.6.7 Disease Severity-wise Patient Population
  • 2.6.8 Treated vs Untreated Patient Population

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Increasing Genetic Testing and Early Diagnosis
  • 3.2.2 Growing Awareness of Rare Diseases
  • 3.2.3 Advancements in Gene Therapy
  • 3.2.4 Expansion of Newborn Screening Programs
• 3.3 Market Restraints
  • 3.3.1 High Cost of Therapy
  • 3.3.2 Limited Patient Accessibility
  • 3.3.3 Regulatory Challenges
  • 3.3.4 Small Patient Pool
• 3.4 Market Opportunities
  • 3.4.1 Precision Medicine Approaches
  • 3.4.2 Emerging Gene Editing Technologies
  • 3.4.3 Expansion in Emerging Markets
  • 3.4.4 Improved Carrier Screening Programs
• 3.5 Porter's Five Forces Analysis
  • 3.5.1 Threat of New Entrants
  • 3.5.2 Bargaining Power of Suppliers
  • 3.5.3 Bargaining Power of Buyers
  • 3.5.4 Threat of Substitutes
  • 3.5.5 Competitive Rivalry

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis of Approved Therapies
• 4.4 Patient Assistance Programs
• 4.5 Rare Disease Funding Initiatives
• 4.6 Healthcare Infrastructure and Treatment Accessibility

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends in DMD
  • 5.1.1 Gene Replacement Therapy
  • 5.1.2 Exon Skipping Technologies
  • 5.1.3 Gene Editing Approaches
  • 5.1.4 Muscle Regeneration Therapies
  • 5.1.5 Anti-inflammatory and Supportive Therapies
• 5.2 Pipeline Landscape by Development Stage
  • 5.2.1 Phase I Pipeline Candidates
  • 5.2.2 Phase II Pipeline Candidates
  • 5.2.3 Phase III Pipeline Candidates
• 5.3 Pipeline Landscape by Mechanism of Action
  • 5.3.1 Micro-dystrophin Gene Therapy
  • 5.3.2 Exon Skipping Therapy
  • 5.3.3 Histone Deacetylase Inhibition
  • 5.3.4 Gene Editing Technologies
  • 5.3.5 Muscle Preservation Therapies
• 5.4 Pipeline Landscape by Modality
  • 5.4.1 Gene Therapies
  • 5.4.2 Antisense Oligonucleotides
  • 5.4.3 Small Molecules
  • 5.4.4 Biologics

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Standard of Care
  • 6.2.1 Corticosteroids
  • 6.2.2 Cardiac Management
  • 6.2.3 Respiratory Management
  • 6.2.4 Physical Therapy and Rehabilitation
• 6.3 Approved Therapies Overview
  • 6.3.1 Gene Therapies
  • 6.3.2 Exon Skipping Therapies
  • 6.3.3 Corticosteroid Therapies
  • 6.3.4 Histone Deacetylase Inhibitors
• 6.4 Treatment Algorithm
• 6.5 Emerging Treatment Approaches
• 6.6 Comparative Analysis of Available Therapies

7. Global Duchenne Muscular Dystrophy Patient Population Analysis Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Size by Therapy Type
• 7.5 Market Size by Route of Administration
• 7.6 Market Size by Distribution Channel
• 7.7 Market Size by End User
• 7.8 Market Attractiveness Analysis

8. Global Duchenne Muscular Dystrophy Patient Population Analysis Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Gene Therapy
  • 8.1.2 Exon Skipping Therapy
  • 8.1.3 Corticosteroids
  • 8.1.4 Supportive Therapies
• 8.2 By Route of Administration
  • 8.2.1 Intravenous
  • 8.2.2 Oral
  • 8.2.3 Others
• 8.3 By Patient Age Group
  • 8.3.1 Pediatric
  • 8.3.2 Adolescent
  • 8.3.3 Adult
• 8.3 By Care Setting
  • 8.3.1 Hospitals
  • 8.3.2 Specialty Clinics
  • 8.3.3 Home Care Settings
• 8.4 By Distribution Channel
  • 8.4.1 Hospital Pharmacies
  • 8.4.2 Retail & Specialty Pharmacies
  • 8.4.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 Rare Disease Regulatory Pathways
• 11.3 Orphan Drug Designation Framework
• 11.4 United States Regulatory Framework (FDA)
• 11.5 Europe Regulatory Framework (EMA)
• 11.6 Japan Regulatory Framework (PMDA)
• 11.7 India Regulatory Framework (CDSCO)
• 11.8 China Regulatory Framework (NMPA)
• 11.9 Reimbursement and Market Access Policies
• 11.10 Patient Advocacy and Rare Disease Policies

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness Analysis
• 12.5 Strategic Collaborations and Partnerships
• 12.6 Mergers and Acquisitions
• 12.7 Licensing Agreements
• 12.8 Recent Developments

13. Company Profiles

• 13.1 Sarepta Therapeutics
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products
    • 13.1.2.1 Elevidys (delandistrogene moxeparvovec-rokl)
    • 13.1.2.2 Exondys 51 (eteplirsen)
    • 13.1.2.3 Vyondys 53 (golodirsen)
    • 13.1.2.4 Amondys 45 (casimersen)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Portfolio
  • 13.1.5 Recent Developments
• 13.2 PTC Therapeutics
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products
    • 13.2.2.1 Emflaza (deflazacort)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Portfolio
  • 13.2.5 Recent Developments
• 13.3 Santhera Pharmaceuticals
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products
    • 13.3.2.1 Agamere (vamorolone)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Recent Developments
• 13.4 NS Pharma
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products
    • 13.4.2.1 Viltepso (viltolarsen)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Recent Developments
• 13.5 Italfarmaco
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products
    • 13.5.2.1 Duvyzat (givinostat)
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Recent Developments
• 13.6 Dyne Therapeutics
  • 13.6.1 Company Overview
  • 13.6.2 Pipeline Portfolio
    • 13.6.2.1 DYNE-251 (Phase II)
  • 13.6.3 Key Indications
  • 13.6.4 Recent Developments
• 13.7 REGENXBIO
  • 13.7.1 Company Overview
  • 13.7.2 Pipeline Portfolio
    • 13.7.2.1 RGX-202 (Phase I/II)
  • 13.7.3 Key Indications
  • 13.7.4 Recent Developments
• 13.8 Solid Biosciences
  • 13.8.1 Company Overview
  • 13.8.2 Pipeline Portfolio
    • 13.8.2.1 SGT-003
  • 13.8.3 Key Indications
  • 13.8.4 Recent Developments
• 13.9 Wave Life Sciences
  • 13.9.1 Company Overview
  • 13.9.2 Pipeline Portfolio
    • 13.9.2.1 WVE-N531
  • 13.9.3 Key Indications
  • 13.9.4 Recent Developments
• 13.10 PepGen
  • 13.10.1 Company Overview
  • 13.10.2 Pipeline Portfolio
    • 13.10.2.1 PGN-EDO51
  • 13.10.3 Key Indications
  • 13.10.4 Recent Developments

14. Future Outlook

• 14.1 Future Patient Population Trends
• 14.2 Evolution of Genetic Screening Programs
• 14.3 Impact of Gene Therapy Adoption
• 14.4 Emerging Technologies and Precision Medicine
• 14.5 Forecast of Treatment Uptake
• 14.6 Strategic Recommendations

15. Methodology

• 15.1 Research Scope and Objectives
• 15.2 Data Collection Methodology
• 15.3 Epidemiology Modeling Approach
• 15.4 Secondary Research Sources
• 15.5 Primary Research Methodology
• 15.6 Market Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations and Definitions